EFFECTIVENESS AND SAFETY OF BIOSIMILAR ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINAL DISEASES: A Systematic Review and Meta-Analysis.
Bhadra U Pandya, Andrew Mihalache, Ryan S Huang et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effectiveness and safety of biosimilar antivascular endothelial growth factor (VEGF) compared to reference anti-VEGF injections for retinal diseases. Analyzing 25 studies, the results indicated no significant differences in visual acuity or retinal thickness outcomes, with moderate to high certainty in the evidence. The follow-up duration ranged from 12 to 63.6 weeks.
Key findings
- No significant differences in final visual acuity between biosimilar and reference anti-VEGF treatments.
- Change in retinal thickness showed no significant variation across treatment types.
- Adverse event incidence was comparable between biosimilar and reference anti-VEGF injections.
- Evidence quality was assessed as moderate to high certainty.
Why it matters
Understanding the comparative effectiveness and safety of biosimilar anti-VEGF treatments is crucial for clinicians in making informed decisions about retinal disease management, especially as biosimilars become more prevalent in clinical practice.